Mirtadepi (Mirtazapine)

Mirtazapine, the active ingredient in Mirtadepi, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients. It works by enhancing noradrenergic and serotonergic neurotransmission, which helps alleviate depressive symptoms such as low mood, loss of interest, and sleep disturbances.

GNH USA supplies Mirtadepi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Mirtazapine, marketed as Mirtadepi, is used within the antidepressant therapeutic class to manage depressive conditions.

- Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Treatment‑resistant depression: may be added when first‑line agents do not achieve adequate response. - Depression with insomnia or weight loss: improves sleep quality and stimulates appetite, aiding overall recovery.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or worsening depression - Severe hypotension or syncope

When prescribing Mirtazapine, clinicians should consider several safety precautions to minimize risk.

- Monitor mood: watch for worsening depression or emergence of suicidal thoughts. - Assess liver function: evaluate hepatic status before initiation and during therapy. - Cardiovascular caution: use carefully in patients with existing heart disease or hypotension. - Avoid abrupt discontinuation: taper the dose to reduce withdrawal symptoms. - Pregnancy and lactation: prescribe only if potential benefits outweigh risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate hypertensive crisis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise mirtazapine plasma concentrations. - Central nervous system depressants (alcohol, benzodiazepines): may enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase drug levels modestly. - Anticholinergic agents: additive dry‑mouth and constipation effects. - Other serotonergic drugs (SSRIs, SNRIs, tramadol): risk of serotonin syndrome, monitor for symptoms.